


Company

Thyas Co. Ltd.


Presenter

Yasumichi
Hitoshi

- A spin-off venture from Center for iPS Cell Research and Application, Kyoto University, a world leader of iPSC research
- Established with supports provided by Kyoto iCAP, Kyoto U's VC
- Focused on development of autologous immunotherapy utilizing rejuvenated T cells with iPS Cell technologies for cancers
- Equipped with a strong patent portfolio and iPSC platform technologies
- FIH in 2020

 Thyas Immunotherapy Utilizing A Nobel Prize-winning
 Technology to Rejuvenate Exhausted T cells
 


Testing Thyas T cell Therapy in Human in 2020



#: Plan to launch the products in Japan under the act on regenerative medicine products